HLB Co., Ltd.

KOSDAQ 028300.KQ

HLB Co., Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: -46.59

HLB Co., Ltd. Price to Earnings Ratio (P/E) is -46.59 on January 14, 2025, a -56.87% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

HLB Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is -28.45 on January 17, 2024, which is 38.93% above the current Price to Earnings Ratio (P/E).
HLB Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is -80.06 on March 26, 2024, which is -71.83% below the current Price to Earnings Ratio (P/E).
HLB Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -51.33.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

KOSDAQ: 028300.KQ

HLB Co., Ltd.

CEO	Mr. Jung-Min Park
IPO Date	Dec. 24, 2008
Location	South Korea
Headquarters	216-53, Dangwol-ro
Employees	150
Sector	Industrials
Industries Shipbuilding Pharmaceuticals

Description

HLB Co., Ltd. manufactures pharmaceutical products, and builds ships. It manufactures and sells various types of lifeboats for marine plants, drill ships, and cruise vessels in South Korea. The company offers conventional type lifeboats, free fall type lifeboats, and rescue boats. It also provides marine and yacht engines; hooks; RIB, patrol, fishing, aluminum, and leisure boats; fishery inspection ships; and safety goods, as well as lifeboat and davit inspection and repair services, service engineering training, and spare parts for lifeboats and davits. In addition, the company develops Riboseranib, a targeted anti-cancer agent; and Apilia that is used for the treatment for ovarian cancer. HLB Co., Ltd. was founded in 1975 and is headquartered in Ulsan, South Korea.

Key trends

Past 5 years